Galina Kuznetsov

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index3.4kcitations77works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(19), Click Chemistry and Applications(16), Cancer-related gene regulation(15), Epigenetics and DNA Methylation(10), Microbial Natural Products and Biosynthesis(9)

Publications77 total

Supplementary Table 1 from Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i>-Mutant Non-Hodgkin Lymphoma
2023Open Access
Figures S20-S23 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Figures S13-S19 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Tables S1-S2 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Figures S11-S12 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Figures S7-S10 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Supplementary Methods, Figure Legends from Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i>-Mutant Non-Hodgkin Lymphoma
2023Open Access
Supplementary Table 2 from Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i>-Mutant Non-Hodgkin Lymphoma
2023Open Access
Tables S3-S4 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Figures S13-S19 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Figures S11-S12 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Supplementary Methods, Figure Legends from Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i>-Mutant Non-Hodgkin Lymphoma
2023Open Access
Figures S1-S6 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Data from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Data from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Figures S7-S10 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Supplementary Table 2 from Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <i>EZH2</i>-Mutant Non-Hodgkin Lymphoma
2023Open Access
Tables S1-S2 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Tables S3-S4 from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
Supplementary Methods from Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Sergei Agoulnik(15), Manav Korpal(11), Xiaoling Puyang(11), Craig Furman(11), Peter Fekkes(11), Markus Warmuth(11), Bruce A. Littlefield(10), Zhenhua J. Wu(10), Sean Irwin(10), Jaya Julie Joshi(10), Nicholas Larsen(10), Namita Kumar(9), Heike Keilhack(9), Vanitha Subramanian(9), Victoria Rimkunas(9), Peter G. Smith(9), Ming‐Hong Hao(9), Deepti Banka(9), Benjamin Caleb(9), Sean Eckley(9)